I've been trying to get an idea of the answer to t
Post# of 148179
I would think that strong data, and a ph3 trial might cause the institutional money to hold tight.
Also, it is my belief that strong results coupled with BP paper and a moderate amount of publicity, would cause oh 3 trials to be enrolled fairly quickly. The faster enrollment, the shorter the duration of a dip would be.